He Yongli, Cai Zhiyou, Chen Yangmei
a Department of Neurology , The Second Affiliated Hospital of Chongqing Medical University , Chongqing , China.
b Department of Neurology , Chongqing General Hospital , Chongqing , China.
Int J Neurosci. 2018 Dec;128(12):1180-1187. doi: 10.1080/00207454.2018.1481065. Epub 2018 Jun 8.
The S-100β levels are associated with a variety of acute disorders and other chronic diseases, such as head injury, stroke, metastatic melanoma, cardiac surgery, bone fractures, burns and contusions. The serum S-100β levels seem to increase with the volume of tissue damage. Higher serum S-100β levels have been observed after brain damage or stroke. A number of studies have evidenced the clinical value of S-100β in the diagnosis and prognosis of stroke while the S-100β marker is elevated in the peripheral blood during the acute phase of stroke. However, the clinical usefulness of S-100β biomarker in the diagnosis and prognosis of stroke has a limitation due to its low discriminating ability in stroke diagnosis and prognosis.
S-100β水平与多种急性疾病和其他慢性疾病相关，如头部损伤、中风、转移性黑色素瘤、心脏手术、骨折、烧伤和挫伤。血清S-100β水平似乎随组织损伤量的增加而升高。脑损伤或中风后观察到较高的血清S-100β水平。多项研究证明了S-100β在中风诊断和预后中的临床价值，而在中风急性期外周血中S-100β标志物会升高。然而，S-100β生物标志物在中风诊断和预后中的临床实用性存在局限性，因为其在中风诊断和预后中的鉴别能力较低。
